2 results match your criteria: "Keyaki Naika Clinic[Affiliation]"
Background: Both combination therapies of an angiotensin II receptor blocker (ARB) with the thiazide diuretic hydrochlorothiazide (HCTZ) and an ARB with a calcium channel blocker (CCB) are recommended to achieve blood pressure (BP) goals in antihypertensive treatment. However, although HCTZ is known to have unfavorable effects on lipid metabolism, the effects of HCTZ in the ARB + HCTZ combination on lipid metabolism have not been fully elucidated.
Objective: The aim of this study was to compare the effects on lipid metabolism of combination treatment with the ARB losartan + HCTZ and losartan + the CCB amlodipine and to assess the efficacy in BP lowering of these 2 combination therapies.
Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
J Cardiol
March 2013
Keyaki Naika Clinic, 3-1-7-102 Namiki, Tokorozawa, Saitama, Japan.
Article Synopsis
- Statins like pravastatin help prevent heart problems, but their effectiveness varies based on different types of cholesterol issues (dyslipidemia).
- In a study with 7,832 Japanese patients, those taking pravastatin saw lower risks of heart disease compared to those just on a diet, especially those with phenotype IIa dyslipidemia.
- However, patients with phenotype IIb dyslipidemia didn't benefit as much from pravastatin, even though they had higher risks due to lower good cholesterol levels.